RecruitingNCT07798323
Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.
Sponsor
Scott Raymond
Enrollment
30 participants
Start Date
Sep 1, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).
Eligibility
Min Age: 50 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with macular degeneration. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years to 80 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07798323
Related Trials
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT0744022591 locations
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148104 locations
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT0677977365 locations
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT0749656763 locations
Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration
NCT07367282